Trials / Active Not Recruiting
Active Not RecruitingNCT06724809
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
An Open-label, Single-arm, Multi-Center, Interventional Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adult Participants With Anti-Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in Chinese Adults with Neuromyelitis Optica Spectrum Disorders (NMOSD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eculizumab | Participants will receive eculizumab by intravenous (IV) infusion for 52 weeks. |
Timeline
- Start date
- 2025-01-16
- Primary completion
- 2026-12-07
- Completion
- 2026-12-07
- First posted
- 2024-12-09
- Last updated
- 2025-12-19
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06724809. Inclusion in this directory is not an endorsement.